Vical Inc. (VICL) Raised to “Buy” at Zacks Investment Research
Vical Inc. (NASDAQ:VICL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday. The brokerage presently has a $3.50 price objective on the stock. Zacks Investment Research’s target price points to a potential upside of 14.38% from the company’s current price.
According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “
Separately, HC Wainwright reissued a “buy” rating on shares of Vical in a research report on Tuesday, July 19th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/vical-inc-vicl-raised-to-buy-at-zacks-investment-research.html
Vical (NASDAQ:VICL) opened at 3.06 on Wednesday. The company’s market cap is $28.17 million. The company’s 50 day moving average price is $3.99 and its 200 day moving average price is $4.09. Vical has a 52-week low of $2.80 and a 52-week high of $5.50.
Vical (NASDAQ:VICL) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.14. The business had revenue of $4.10 million for the quarter, compared to the consensus estimate of $4.50 million. Vical had a negative return on equity of 14.18% and a negative net margin of 30.81%. Equities research analysts anticipate that Vical will post ($0.86) EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in VICL. BlackRock Fund Advisors boosted its stake in Vical by 32.5% in the second quarter. BlackRock Fund Advisors now owns 23,459 shares of the company’s stock valued at $106,000 after buying an additional 5,750 shares during the last quarter. Eagle Global Advisors LLC acquired a new stake in Vical during the second quarter valued at $178,000. ClariVest Asset Management LLC acquired a new stake in Vical during the second quarter valued at $208,000. Finally, Renaissance Technologies LLC boosted its stake in Vical by 29.8% in the first quarter. Renaissance Technologies LLC now owns 2,073,599 shares of the company’s stock valued at $811,000 after buying an additional 476,499 shares during the last quarter. Hedge funds and other institutional investors own 31.48% of the company’s stock.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.